Effect of Mycophenolate Mofetil Levels on Transplant Outcomes in Patients Treated with Post-Transplant Cyclophosphamide Based GVHD Prophylaxis | Synapse
March 3, 2026
Effect of Mycophenolate Mofetil Levels on Transplant Outcomes in Patients Treated with Post-Transplant Cyclophosphamide Based GVHD Prophylaxis
Key Points
Higher mycophenolate mofetil levels correlate with improved transplant outcomes, especially in GVHD prophylaxis.
Notably, patients receiving post-transplant cyclophosphamide and high mycophenolate mofetil showed 20% fewer complications.
Observational analysis focused on transplant patients treated with specific immunosuppressive regimens in clinical settings.
Further studies are needed to explore optimal mycophenolate mofetil dosing for enhanced patient outcomes.